Clinical Trials

Our Ophthalmic Studies

The clinician-scientists at Cascade Medical Research Institute (CMRI) lead ophthalmic studies that bring tomorrow's promise of better vision and outcomes to patients today.

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI)

Objective. To evaluate the efficacy of KSI-101 compared to sham.

NCT Number
NCT06990399 (PEAK) · NCT06996080 (PINNACLE)
Sponsor
Kodiak Sciences
Principal Investigator
Robert Beardsley, MD
Coordinator
Lexi Price-Breeze

Randomized Trial Comparing Immediate Versus Deferred Surgery for Symptomatic Epiretinal Membranes

Objective. Compare visual acuity outcomes at 36 months between eyes randomized to immediate versus deferred surgery.

NCT Number
NCT05145491
Sponsor
Diabetic Retinopathy Clinical Research Network
Principal Investigator
Allan A. Hunter, MD
Coordinator
Liz Carskadon Bale

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy (GA)

Objective. To evaluate the effect of systemic C5 inhibition on GA lesion growth over 52 weeks.

NCT Number
NCT06541704
Sponsor
Regeneron Pharmaceuticals
Principal Investigator
Allan A. Hunter, MD
Coordinator
Liz Carskadon Bale
GALLOP

A phase 2, randomized, placebo-controlled, multicenter, masked study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of multidose apl-3007 in combination with syfovre/pegcetacoplan (apl-2) in patients diagnosed with geographic atrophy secondary to age-related macular degeneration

Objective. To evaluate the efficacy of multidose APL-3007 and Syfovre/pegcetacoplan (APL-2) compared to Syfovre alone

NCT Number
NCT07215390
Sponsor
Apellis
Principal Investigator
Allan A. Hunter, MD
Coordinator
Kierstin Kimbell
TORRONTES

A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)

Objective. To evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept.

NCT Number
NCT07496567
Sponsor
EyeBiotech Ltd.
Principal Investigator
Allan A. Hunter, MD
Coordinator
Liz Carskadon Bale

Want to Learn More and Stay Up to Date With Current Research at CMRI?

Subscribe to our quarterly newsletter.

We never share your address. Unsubscribe in one click from any issue.